RS2 Healthcare Partners

What RS2 Healthcare Partners does

RS2 Healthcare Partners (formerly Riverside Partners) is a Boston-based private equity firm founded in 1989 that invests in lower-middle-market companies with $3–15 million in EBITDA and $20–200 million in revenue, primarily in healthcare and, historically, technology. Following a May 2026 rebrand, the firm has formalized an exclusive focus on healthcare investing across subsectors including healthcare IT, medical products and equipment, provider and payer services, contract manufacturing, lab products and services, and pharma services. The firm operates a traditional fund-based private equity model, managing approximately $1.1 billion of equity capital across six funds, with Riverside Fund V (2012) having raised $561 million.

The firm's core offering is control and growth-equity capital paired with operational support from a team of former operators and consultants. Portfolio company examples include Revecore (revenue integrity for ~1,200 hospitals), Loftware (enterprise labeling software generating approximately $125 million in revenue and serving over 10,000 customers across 100+ countries), Sequoia and Syner-G (life sciences consulting and CMC/regulatory services, now combined), UnisLink (revenue cycle and population health management), Net32 (dental supplies eCommerce), HealthDrive, and Convergence Networks (managed IT/cybersecurity). RS2 earns revenue through management fees on committed and invested capital from institutional limited partners and through carried interest on successful portfolio company exits.

RS2 pursues an active buy-and-build value creation model, with portfolio companies executing add-on acquisitions (UnisLink's 2023 acquisitions of AQREVA, Doctors' Resource Specialists, and HST; Revecore's acquisitions of Kemberton and Cura; Sequoia/Syner-G combinations). Realizations have included the 2026 Loftware continuation vehicle with AKKR Strategic Capital, the 2023 partial sale of Loftware to Accel-KKR, the 2022 Revecore partial exit to GrowthCurve Capital, and historical exits of Vocollect ($190M to Intermec), IZI Medical Products ($93M to Landauer), BioAgilytix (to Cobepa), and Eliassen Group (to Stone Point Capital). The firm has been named to the Inc. Founder-Friendly Investors list for four consecutive years (2022–2025).

Name

RS2 Healthcare Partners

Legal name

Riverside Partners, LLC

Website

https://rs2healthcare.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

RS2 Healthcare Partners is a Boston-based private equity firm (founded 1989, rebranded 2026) that invests $3–15M EBITDA growth and control capital in lower-middle-market healthcare companies across North America, managing approximately $1.1 billion in equity capital across six funds.

Ownership category

akta.pro rank

Product category

Private Equity Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Business Services (B2B) Growth Equity (FSANACAD)

akta.pro secondary industries

LP Secondaries — Growth Equity Funds (FSAHALAC), Secondary Fund Stakes (GP/Manager Stakes in Secondary GPs) (FSANAFAD)

Keywords

• Private equity investing
• Growth equity capital
• Healthcare buyouts
• Lower middle market
• Venture capital partnerships

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund Management Fees: Generates management fees from managing private equity funds for institutional investors
2. Carried Interest: Earns performance-based carried interest from successful portfolio company exits

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

RS2 Healthcare Partners is a Boston-based private equity firm that makes control investments and growth equity investments in lower middle market healthcare companies with $3-15M EBITDA across North America. The firm manages approximately $1.1 billion of equity capital from institutional limited partners and provides portfolio companies with capital, sector expertise, and an advisory network to accelerate growth alongside management teams.

Product overview

RS2 Healthcare Partners (formerly Riverside Partners) is a single private equity firm offering. The firm is not structured as a platform with modules but rather provides investment capital, industry expertise, and operational support to portfolio companies. The firm targets companies with $3-15 million EBITDA in healthcare and technology sectors across North America.

Differentiator

Problem solved

Functional benefit

Products and services

• Riverside Fund V, L.P. Riverside Fund V, L.P. is a $561 million private equity fund raised in 2012 that invests growth equity and makes control investments in lower middle market healthcare and technology companies across North America. The fund is offered to institutional limited partners as a commingled investment vehicle.
• RS2 Healthcare Partners Sixth Fund (Current Investing Fund) The firm's current sixth private equity fund, representing approximately $1.1 billion of equity capital under management, invests growth equity and makes control investments in lower middle market healthcare companies with $3-15M EBITDA across North America. The fund is offered to institutional limited partners as a commingled investment vehicle.
• Loftware Single-Asset Continuation Vehicle The Loftware Single-Asset Continuation Vehicle is a discrete investment vehicle closed in 2026 with AKKR Strategic Capital as lead investor, providing dedicated growth capital to Loftware while enabling RS2 Healthcare Partners to deploy capital toward new platform investments.

Quantifiable outcome

• Multiple successful exits including Vocollect ($190M to Intermec), IZI Medical Products ($93M to Landauer), IPA to Roper Industries, BioAgilytix to Cobepa, Eliassen Group to Stone Point Capital
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Audax Private Equity: Boston-based lower middle market PE firm with a similar focus on healthcare and technology companies in the $5-50M EBITDA range. Both firms pursue control investments with management rollover and are comparable in scale and strategy.
• Webster Equity Partners: Healthcare-services focused lower middle market PE firm based in Boston. Webster's exclusive healthcare focus and similar deal-size range makes it the most direct competitor; two of RS2's recent hires (Alicia Alexander, Joshua Griffin) came from Webster.
• Enhanced Healthcare Partners: Healthcare-only middle market PE firm making control and growth equity investments. Patrick Furlong, an RS2 Partner, previously worked at Enhanced Healthcare, indicating a direct talent and strategy overlap.
• Excellere Partners: Lower middle market PE firm with healthcare and technology verticals, headquartered in Denver. Similar investment criteria and sector focus to RS2 makes it a direct strategic peer.
• Flexpoint Ford: Healthcare and financial services focused PE firm. Patrick Furlong joined RS2 from Flexpoint Ford, indicating direct talent and strategy overlap, with comparable lower middle market healthcare investing approach.
• Amulet Capital Partners: Healthcare-only middle market PE firm with comparable investment size and strategy, making control investments in healthcare services, medical products, and pharma services businesses.
• Cressey & Company: Healthcare-focused PE firm making growth equity investments in lower middle market healthcare services and technology companies. Comparable sector specialization and investment size range.
• Varsity Healthcare Partners: Lower middle market healthcare services PE firm with similar focus on control investments and management partnerships. Closely comparable in deal size, sector focus, and partnership approach.

Broad incumbents

• Linden Capital Partners: Healthcare-focused PE firm that is significantly larger than RS2 and concentrates on buyouts of healthcare services and pharma services businesses. Comparable by sector focus but operates at higher end of middle market.
• Avista Capital Partners: Healthcare-focused middle market PE firm with substantially larger AUM. Comparable healthcare sector focus and growth equity strategy but generally invests in larger platforms than RS2's lower middle market sweet spot.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/riversideboston

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A25 records

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RS2 Healthcare Partners